Bevacizumab in Treating Young Patients With Refractory Solid Tumors

NCT00085111 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

NIH

Sponsor class

Conditions

Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

BIOLOGICAL: bevacizumab

Sponsor

National Cancer Institute (NCI)